JP2006513239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513239A5 JP2006513239A5 JP2004565263A JP2004565263A JP2006513239A5 JP 2006513239 A5 JP2006513239 A5 JP 2006513239A5 JP 2004565263 A JP2004565263 A JP 2004565263A JP 2004565263 A JP2004565263 A JP 2004565263A JP 2006513239 A5 JP2006513239 A5 JP 2006513239A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- drug
- composition according
- acid labile
- acid content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 239000002702 enteric coating Substances 0.000 claims 4
- 238000009505 enteric coating Methods 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 239000011347 resin Substances 0.000 claims 3
- 229920005989 resin Polymers 0.000 claims 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical group C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 239000003456 ion exchange resin Substances 0.000 claims 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 206010063655 Erosive oesophagitis Diseases 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 229950007395 leminoprazole Drugs 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 229960005019 pantoprazole Drugs 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43628702P | 2002-12-23 | 2002-12-23 | |
| PCT/US2003/038983 WO2004060357A1 (en) | 2002-12-23 | 2003-12-09 | Acid labile drug compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006513239A JP2006513239A (ja) | 2006-04-20 |
| JP2006513239A5 true JP2006513239A5 (enExample) | 2006-12-28 |
Family
ID=32713062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004565263A Pending JP2006513239A (ja) | 2002-12-23 | 2003-12-09 | 酸不安定性薬剤含有組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070036851A1 (enExample) |
| EP (1) | EP1581196A4 (enExample) |
| JP (1) | JP2006513239A (enExample) |
| AU (1) | AU2003297736A1 (enExample) |
| CA (1) | CA2511540A1 (enExample) |
| WO (1) | WO2004060357A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2018160B1 (en) * | 2006-03-16 | 2011-12-14 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| BR112013020537B1 (pt) * | 2011-02-15 | 2021-09-08 | Tris Pharma, Inc | Suspensão oral e mescla de pó de liberação prolongada aquosa de metilfenidato, método para fornecer um produto em suspensão líquida de metilfenidato, e formulação |
| ES2717469T3 (es) | 2012-08-15 | 2019-06-21 | Tris Pharma Inc | Comprimido masticable de metilfenidato de liberación prolongada |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| PT854718E (pt) * | 1995-09-21 | 2004-08-31 | Pharma Pass Ii Llc | Composicao farmaceutica contendo um benzimidazole acido-labil e processo para a sua preparacao |
| SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| KR100314351B1 (ko) * | 1998-10-01 | 2002-03-21 | 민경윤 | 벤즈이미다졸유도체의장용성제제및그제조방법 |
| WO2000040224A1 (en) * | 1999-01-07 | 2000-07-13 | Elan Corporation, Plc | Multiparticulate oral dosage forms |
-
2003
- 2003-12-09 JP JP2004565263A patent/JP2006513239A/ja active Pending
- 2003-12-09 US US10/540,453 patent/US20070036851A1/en not_active Abandoned
- 2003-12-09 CA CA002511540A patent/CA2511540A1/en not_active Abandoned
- 2003-12-09 EP EP03796801A patent/EP1581196A4/en not_active Withdrawn
- 2003-12-09 WO PCT/US2003/038983 patent/WO2004060357A1/en not_active Ceased
- 2003-12-09 AU AU2003297736A patent/AU2003297736A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2170644C (en) | Multiple unit pharmaceutical preparation containing proton pump inhibitor | |
| JP5412021B2 (ja) | オメプラゾール含有医薬製剤 | |
| CA2529984C (en) | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors | |
| JP2008534438A5 (enExample) | ||
| RU2006101082A (ru) | Фармацевтическая композиция с набухающим покрытием | |
| CN1146720A (zh) | 新的药物制剂及其制备方法 | |
| SK1032000A3 (en) | Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production | |
| CA2318008A1 (en) | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound | |
| AU2993795A (en) | Multiple unit tableted dosage form I | |
| HRP20000380A2 (en) | Oral pharmaceutical extended release dosage form | |
| NO328100B1 (no) | Farmasoytisk formulering av omeprazol | |
| JP2011500595A5 (enExample) | ||
| JP2009517466A (ja) | 活性成分として、アセチルサリチル酸と一緒にプロトンポンプ阻害剤を含む経口医薬剤形 | |
| CA2377605A1 (en) | Stable benzimidazole formulation | |
| CN104606146A (zh) | 一种埃索美拉唑镁肠溶微丸制剂及其制备方法 | |
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| JP2006513239A5 (enExample) | ||
| CN103784414A (zh) | 一种埃索美拉唑肠溶片及其制备方法 | |
| EP2496223A2 (en) | Pharmaceutical solid dosage form | |
| CN110785164A (zh) | 包括质子泵抑制剂的口服用固体制剂组合物、包括该组合物的口服用固体制剂及其制造方法 | |
| CA2470609A1 (en) | Tableted oral pharmaceutical dosage form, with an enteric coating, containing a benzimidazole compound labile in an acid medium | |
| CA2733299A1 (en) | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer | |
| CN1251297A (zh) | 一种苯并咪唑的肠溶衣制剂及其制备方法 | |
| RU2007123436A (ru) | Фармацевтическая композиция, содержащая аморфные соединения бензимидазола, и способ ее приготовления | |
| WO2023025231A1 (zh) | 用于干混悬剂的干混悬颗粒及其制备方法和用途 |